AstraZeneca-Ionis Eplontersen granted USFDA fast track designation for transthyretin-mediated amyloid cardiomyopathy Ruchika Sharma10 Feb 2024 3:30 PM ISTCarlsbad: Ionis Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Ionis...
AstraZeneca Wainua gets USFDA nod for adults with polyneuropathy of hereditary transthyretin-mediated amyloidosis Ruchika Sharma24 Dec 2023 2:45 PM ISTUS: AstraZeneca and Ionis' Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary...
Eplontersen feasible gene silencing technique for treating hereditary transthyretin amyloidosis with polyneuropathy: JAMA Medha Baranwal24 Oct 2023 10:00 AM ISTUSA: Eplontersen treatment in adults with hereditary transthyretin (ATTRv) amyloidosis with polyneuropathy resulted in less neuropathy impairment,...
Eplontersen improves neuropathy and QoL in hereditary transthyretin amyloidosis with polyneuropathy: JAMA. Aditi2 Oct 2023 6:45 PM ISTFor managing hereditary transthyretin (ATTRv) amyloidosis, Transthyretin gene silencing is an emerging treatment strategy. However, a recent study has...
AstraZeneca gets right to commercialize Eplontersen in Latin America Ruchika Sharma1 Aug 2023 1:30 PM ISTAstraZeneca paid Ionis USD 20 million to license eplontersen in Latin America.
AstraZeneca, Ionis Pharma seek US nod for Eplontersen after positive trial data Ruchika Sharma21 Jun 2022 3:35 PM ISTThe data from the 35-week interim analysis will be presented at an upcoming medical meeting later this year.
Ionis Eplontersen gets USFDA orphan drug designation Ruchika Sharma26 Jan 2022 10:30 AM ISTCarlsbad: Ionis Pharmaceuticals, Inc. has recently announced that the U.S. Food and Drug Administration (USFDA) has granted orphan drug...
AstraZeneca closes Eplontersen agreement with Ionis Medical Dialogues Bureau2 Jan 2022 10:00 AM ISTUK: AstraZeneca has announced that the company has closed a global development and commercialisation agreement with Ionis Pharmaceuticals, Inc. for...
